41 Prostate Cancer Clinical Trials in San Francisco, CA (2026)

Q: How do I join a clinical trial in San Francisco?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you.

Recruiting Prostate Cancer Studies in San Francisco

NCT04706663Recruiting

Precision-Based Genomics in Prostate Cancer

Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s...

San Francisco, CA2,000 participantsNational Cancer Institute (NCI)

View Study Details

NCT06136650Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Me...

San Francisco, CAPHASE31,314 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07164443Recruiting

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive...

San Francisco, CAPHASE31,203 participantsJanssen Research & Development, LLC

View Study Details

NCT06764485Recruiting

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer....

San Francisco, CAPHASE3960 participantsCelgene

View Study Details

NCT07213674Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone)....

San Francisco, CAPHASE3750 participantsAmgen

View Study Details

NCT07611110Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in ...

San Francisco, CAPHASE3670 participantsAstraZeneca

View Study Details

NCT06579417Recruiting

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa). The study will enroll 500 participants at 5 cli...

San Francisco, CA500 participantsUniversity of California, San Diego

View Study Details

NCT04221542Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate pr...

San Francisco, CAPHASE1479 participantsAmgen

View Study Details

NCT04472338Recruiting

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue...

San Francisco, CA450 participantsUniversity of Washington

View Study Details

NCT05939414Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after defini...

San Francisco, CAPHASE3450 participantsNovartis Pharmaceuticals

View Study Details

NCT07690579Recruiting

Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities

Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proport...

San Francisco, CA350 participantsUniversity of California, San Francisco

View Study Details

NCT07336446Recruiting

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmaco...

San Francisco, CAPHASE1300 participantsAstraZeneca

View Study Details

NCT05519449Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults...

San Francisco, CAPHASE1272 participantsJanux Therapeutics

View Study Details

NCT05396872Recruiting

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

This clinical trial explores and implements methods to improve informed decision making (IDM) regarding precision oncology tests amongst veterans with prostate cancer that may have spread from where i...

San Francisco, CANA250 participantsUniversity of California, San Francisco

View Study Details

NCT05948657Recruiting

Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermedi...

San Francisco, CANA200 participantsWeill Medical College of Cornell University

View Study Details

NCT04986423Recruiting

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 cr...

San Francisco, CAPHASE2200 participantsZenith Epigenetics

View Study Details

NCT07285694Recruiting

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC)....

San Francisco, CAPHASE1190 participantsArsenal Biosciences, Inc.

View Study Details

NCT06391034Recruiting

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy fo...

San Francisco, CAPHASE2161 participantsRobert Bok, MD, PhD

View Study Details

NCT07103018Recruiting

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the ...

San Francisco, CAPHASE1144 participantsK36 Therapeutics, Inc.

View Study Details

NCT05435495Recruiting

Mechanisms of Resistance to PSMA Radioligand Therapy

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses....

San Francisco, CA125 participantsUniversity of California, San Francisco

View Study Details

NCT07287150Recruiting

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or doceta...

San Francisco, CAPHASE2100 participantsHoffmann-La Roche

View Study Details

NCT05888532Recruiting

64Cu-GRIP B in Patients With Advanced Malignancies

This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positr...

San Francisco, CAPHASE191 participantsRahul Aggarwal

View Study Details

NCT02526368Recruiting

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding pros...

San Francisco, CAEARLY_PHASE180 participantsIvan de Kouchkovsky, MD

View Study Details

NCT06171139Recruiting

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the t...

San Francisco, CANA80 participantsUniversity of California, San Francisco

View Study Details

NCT06842498Recruiting

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in th...

San Francisco, CAPHASE275 participantsKyntra Bio

View Study Details

NCT04763980Recruiting

Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer

This clinical trial studies barriers to genetic testing in African American men with prostate cancer and whether tailored, culturally relevant genetic testing education provided by a community-based h...

San Francisco, CANA72 participantsUniversity of California, San Francisco

View Study Details

NCT03821246Recruiting

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunother...

San Francisco, CAPHASE268 participantsDavid Oh

View Study Details

NCT03933670Recruiting

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active survei...

San Francisco, CAPHASE260 participantsUniversity of California, San Francisco

View Study Details

NCT07140900Recruiting

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone....

San Francisco, CAPHASE160 participantsAmgen

View Study Details

NCT06228053Recruiting

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone....

San Francisco, CAPHASE253 participantsSyntrix Biosystems, Inc.

View Study Details

NCT06526299Recruiting

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) an...

San Francisco, CAPHASE251 participantsUniversity of Washington

View Study Details

NCT05766371Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metasta...

San Francisco, CAPHASE248 participantsUniversity of California, San Francisco

View Study Details

NCT07050433Recruiting

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-...

San Francisco, CA48 participantsDuke University

View Study Details

NCT07054346Recruiting

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a ra...

San Francisco, CAPHASE145 participantsThomas Hope

View Study Details

NCT06257693Recruiting

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy....

San Francisco, CAPHASE145 participantsAlessa Therapeutics Inc.

View Study Details

NCT06613100Recruiting

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagon...

San Francisco, CAPHASE140 participantsAmgen

View Study Details

NCT06384222Recruiting

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-n...

San Francisco, CAPHASE232 participantsIvan de Kouchkovsky, MD

View Study Details

NCT07111507Recruiting

A Study of Tarlatamab for People With Prostate Cancer

The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (meta...

San Francisco, CAPHASE232 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05113537Recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has sp...

San Francisco, CAPHASE130 participantsVadim S Koshkin

View Study Details

NCT07145177Recruiting

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-dire...

San Francisco, CAPHASE130 participantsUniversity of California, San Francisco

View Study Details

NCT05665738Recruiting

Two-fraction HDR Monotherapy for Localized Prostate Cancer

This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has bee...

San Francisco, CANA17 participantsUniversity of California, San Francisco

View Study Details

About Prostate Cancer Clinical Trials in San Francisco

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 41 prostate cancer clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 12,125 participants. Research is being sponsored by National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Janssen Research & Development, LLC and 24 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in San Francisco — FAQ

Are there prostate cancer clinical trials in San Francisco?

Yes, there are 41 prostate cancer clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 41 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated September 1, 2026 from ClinicalTrials.gov